MétaCan
Menu
← Back to cohort

Severe Erosive Esophagitis Induced by Crizotinib Therapy: A Case Report and Review of the Literature

2016· article· en· W2977714774 on OpenAlexaff
Kyle J. Fortinsky, Patrick Jung, Zane Gallinger, Rowena Almeida, Piero Tartaro

Bibliographic record

VenueThe American Journal of Gastroenterology · 2016
Typearticle
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsCrizotinibMedicineOdynophagiaEsophagitisNauseaAnaplastic lymphoma kinaseVomitingAdverse effectInternal medicineLung cancerSurgeryDermatologyEsophagus

Abstract

fetched live from OpenAlex

Crizotinib is an oral tyrosine kinase inhibitor used in the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The phase III trial completed prior to approval noted visual disturbances and gastrointestinal symptoms (e.g. nausea, vomiting, and diarrhea) as common adverse events, but no cases of esophagitis were reported. Since then a few case reports have described esophagitis secondary to crizotinib therapy. In all previous reports, esophagitis appears to have developed quite soon (i.e. within 90 days) after initiating or re-initiating crizotinib therapy (see Table 1). We present a woman who developed acute odynophagia and severe erosive esophagitis ten months after beginning crizotinib (see Figure 1). We suspect the provoking factor was a change in her medication administration routine, done to accommodate religious practices during the period of Ramadan. Careful history taking revealed that she had altered her medication schedule as she reported taking her crizotinib earlier in the morning and later in the evening after which she would immediately lay supine, which was much different than her usual routine. Within 2 weeks of this schedule change she began experiencing significant odynophagia. She was on no other medications and biopsies from her endoscopy revealed no signs of candida infection. This unique case suggests that esophagitis related to crizotinib therapy may be directly related to medication administration practices, which can be preventable. Our patient was found to have tumor progression despite therapy so she was started on second line treatment and the crizotinib was not restarted. Her symptoms disappeared within days of stopping the crizotinib and starting twice daily PPI therapy. Our case highlights the importance of patient education surrounding medication administration, which is of utmost importance for cancer patients who require a specific treatment and have few alternative options. Medication administration and any recent changes should always be considered in the differential diagnosis for those presenting with pill esophagitis.Figure 1Table 1: Timing of onset and resolution of symptoms after initiating and discontinuing crizotinib therapy in five previous case reports.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Case report · Consensus signal: Case report
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.006
Threshold uncertainty score0.011

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.002
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0060.006
Science and technology studies0.0020.002
Scholarly communication0.0020.004
Open science0.0020.002
Research integrity0.0050.003
Insufficient payload (model declined to judge)0.0030.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.300
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designCase report
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicLung Cancer Treatments and Mutations→French-language works237,207→